Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates

Ann Neurol. 2004 Nov;56(5):723-7. doi: 10.1002/ana.20279.


To examine the antiparkinsonian effects of blocking glycineB receptors, we designed a pilot study testing the potent and selective antagonist, PAMQX, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. PAMQX had no intrinsic effects but markedly potentiated the antiparkinsonian action of levodopa. In a dose-dependent fashion, coadministration of the glycineB antagonist with levodopa extended the response duration by nearly 60%. It is noteworthy that PAMQX, within a considerable dose range, did not cause ataxia or other side effects. These data indicate that blocking N-methyl-D-aspartate receptors selectively to manipulate dopaminergic-mediated motor responses may be produced effectively by glycineB antagonists.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / therapeutic use*
  • Behavior, Animal
  • Disability Evaluation
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Glycine Agents / administration & dosage*
  • Levodopa / administration & dosage
  • Levodopa / therapeutic use*
  • Macaca mulatta
  • Motor Activity / drug effects
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / drug therapy*
  • Pilot Projects
  • Psychomotor Performance / drug effects
  • Receptors, Glycine / antagonists & inhibitors*


  • Antiparkinson Agents
  • Glycine Agents
  • Receptors, Glycine
  • Levodopa
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine